Immunotherapy to treat malignancy in patients with pre-existing autoimmunity
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunotherapy to treat malignancy in patients with pre-existing autoimmunity
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 8, Issue 1, Pages e000356
Publisher
BMJ
Online
2020-04-17
DOI
10.1136/jitc-2019-000356
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Risk of Toxicity After Initiating Immune Checkpoint Inhibitor Treatment in Patients With Rheumatoid Arthritis
- (2020) Elizaveta Efuni et al. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
- New therapeutic perspectives to manage refractory immune checkpoint-related toxicities
- (2019) Filipe Martins et al. LANCET ONCOLOGY
- Clinical Outcomes of Patients with Advanced Cancer and Pre‐Existing Autoimmune Diseases Treated with Anti‐Programmed Death‐1 Immunotherapy: A Real‐World Transverse Study
- (2019) Alessio Cortellini et al. ONCOLOGIST
- Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
- (2019) Elisabeth Perez-Ruiz et al. NATURE
- Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
- (2019) Filipe Martins et al. Nature Reviews Clinical Oncology
- A Multidisciplinary Toxicity Team for Cancer Immunotherapy–Related Adverse Events
- (2019) Jarushka Naidoo et al. Journal of the National Comprehensive Cancer Network
- Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors
- (2019) Laura C. Kennedy et al. Journal of the National Comprehensive Cancer Network
- A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis
- (2019) Douglas B. Johnson et al. NATURE MEDICINE
- Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab
- (2019) Suzanne L. Topalian et al. JAMA Oncology
- The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis
- (2019) Karthik Suresh et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Preexisting Autoimmune Disease: A Nationwide Multicenter Cohort Study
- (2019) Alice Tison et al. Arthritis & Rheumatology
- Factors Associated With Immune Checkpoint Inhibitor–Related Myocarditis
- (2019) Yoshito Zamami et al. JAMA Oncology
- Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events
- (2019) Yousef R. Badran et al. Journal for ImmunoTherapy of Cancer
- Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
- (2019) Satya Das et al. Journal for ImmunoTherapy of Cancer
- Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease
- (2019) Hamzah Abu-Sbeih et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease
- (2018) Noha Abdel-Wahab et al. ANNALS OF INTERNAL MEDICINE
- Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials
- (2018) Karen Kelly et al. CANCER
- Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders
- (2018) Katharina C. Kähler et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Long-Term Effects of Lifestyle Intervention and Metformin during DPP on Appendicular Lean Mass
- (2018) ANN V. SCHWARTZ et al. DIABETES
- Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease
- (2018) François-Xavier Danlos et al. EUROPEAN JOURNAL OF CANCER
- Safety of Programmed Death–1 Pathway Inhibitors Among Patients With Non–Small-Cell Lung Cancer and Preexisting Autoimmune Disorders
- (2018) Giulia C. Leonardi et al. JOURNAL OF CLINICAL ONCOLOGY
- Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors
- (2018) Michael F. Gowen et al. Journal of Translational Medicine
- Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis
- (2018) Javid J Moslehi et al. LANCET
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of Immune‐Related Adverse Events with Clinical Benefit in Patients with Advanced Non‐Small‐Cell Lung Cancer Treated with Nivolumab
- (2018) Yukihiro Toi et al. ONCOLOGIST
- Brief Report: Cancer Immunotherapy in Patients With Preexisting Rheumatic Disease: The Mayo Clinic Experience
- (2018) Michael D. Richter et al. Arthritis & Rheumatology
- Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
- (2018) Koji Haratani et al. JAMA Oncology
- Managing cancer risk in patients with systemic lupus erythematous
- (2018) Alexandra Ladouceur et al. Expert Review of Clinical Immunology
- Opioids vs Nonopioids for Chronic Back, Hip, or Knee Pain
- (2018) Wenbao Wang et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma
- (2018) Alice Indini et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity
- (2018) Chien-Chun Steven Pai et al. JOURNAL OF CLINICAL INVESTIGATION
- Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors
- (2018) Emma C. de Moel et al. Cancer Immunology Research
- Profiling Preexisting Antibodies in Patients Treated With Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer
- (2018) Yukihiro Toi et al. JAMA Oncology
- Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity
- (2017) Ralf Gutzmer et al. EUROPEAN JOURNAL OF CANCER
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
- (2017) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
- (2017) Florie Bertrand et al. Nature Communications
- The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma
- (2016) B. Lee et al. ANNALS OF ONCOLOGY
- Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
- (2016) A. M. Menzies et al. ANNALS OF ONCOLOGY
- Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire
- (2016) David Y. Oh et al. CANCER RESEARCH
- Fulminant Myocarditis with Combination Immune Checkpoint Blockade
- (2016) Douglas B. Johnson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- (2016) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
- (2016) Douglas B. Johnson et al. JAMA Oncology
- Prevalence of Autoimmune Disease Among Patients With Lung Cancer
- (2016) Saad A. Khan et al. JAMA Oncology
- Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
- (2015) M. Freeman-Keller et al. CLINICAL CANCER RESEARCH
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab in patients with melanoma and autoimmune disease
- (2014) Chrisann Kyi et al. Journal for ImmunoTherapy of Cancer
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Programmed Cell Death 1 Suppresses B-1b Cell Expansion and Long-Lived IgG Production in Response to T Cell-Independent Type 2 Antigens
- (2011) Karen M. Haas JOURNAL OF IMMUNOLOGY
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells
- (2010) Kim L Good-Jacobson et al. NATURE IMMUNOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Applications of Diabetes Antibody Testing
- (2009) Polly J. Bingley JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started